Education
About Us
Working with TipRanks
Follow Us
Vor Biopharma, Inc. (VOR)
:VOR
VOR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.13 - $1.80
Previous CloseN/A
Volume424.02K
Average Volume (3M)12.77M
Market Cap
$69.28M
Enterprise Value$244.22M
Total Cash (Recent Filing)$60.03M
Total Debt (Recent Filing)$30.78M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Aug 07, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding124,959,520
10 Day Avg. Volume29,828,066
30 Day Avg. Volume12,768,962
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)1.05
Price to Sales (P/S)0.00
P/FCF Ratio-2.81
Enterprise Value/Market Cap3.53
Enterprise Value/Revenue9.99
Enterprise Value/Gross Profit-271.36
Enterprise Value/Ebitda-0.51
Forecast
1Y Price Target
$0.32Price Target Upside-41.82% Downside
Rating ConsensusHold
Number of Analyst Covering7
Vor Biopharma News
PremiumCompany Announcements
Vor Biopharma Secures License Agreement with RemeGenBulls Say, Bears Say
Bulls Say
Clinical TrialsFDA does not require additional data to start the Phase III trial and agreed with VOR on its design.
Investment ThesisDespite the price target adjustment, the underlying investment thesis is based on the strong clinical and commercial potential of Vor Biopharma's assets and technology.
Product PotentialThe transformative potential of trem-cel and VCAR33 in treating AML/MDS is supported by clinical data, enhancing the company's scientific and clinical thesis.
Bears Say
Stock DowngradeDespite having a healthy balance sheet, the uncertainties due to potential strategic alternatives have led to a downgrade of VOR stock to Neutral from Buy.
Strategic UncertaintyVor Biopharma, Inc. announced the initiation of a strategic review to explore options to maximize shareholder value, including a potential sale of assets or the company itself, due to challenging financing conditions and accumulated clinical data.
Workforce ReductionThe company is winding down all clinical and manufacturing operations, retaining only eight essential employees, leading to a workforce reduction of approximately 95%.
Ownership Overview
Currently, No data available
---
VOR FAQ
What was Vor Biopharma, Inc.’s price range in the past 12 months?
Vor Biopharma, Inc. lowest stock price was $0.13 and its highest was $1.80 in the past 12 months.
What is Vor Biopharma, Inc.’s market cap?
Vor Biopharma, Inc.’s market cap is $69.28M.
When is Vor Biopharma, Inc.’s upcoming earnings report date?
Vor Biopharma, Inc.’s upcoming earnings report date is Aug 07, 2025 which is in 41 days.
How were Vor Biopharma, Inc.’s earnings last quarter?
Vor Biopharma, Inc. released its earnings results on May 08, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.263 by $0.013.
Is Vor Biopharma, Inc. overvalued?
According to Wall Street analysts Vor Biopharma, Inc.’s price is currently Overvalued.
Does Vor Biopharma, Inc. pay dividends?
Vor Biopharma, Inc. does not currently pay dividends.
What is Vor Biopharma, Inc.’s EPS estimate?
Vor Biopharma, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Vor Biopharma, Inc. have?
Vor Biopharma, Inc. has 124,959,520 shares outstanding.
What happened to Vor Biopharma, Inc.’s price movement after its last earnings report?
Vor Biopharma, Inc. reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.263. Following the earnings report the stock price went down -70.37%.
Which hedge fund is a major shareholder of Vor Biopharma, Inc.?
Currently, no hedge funds are holding shares in VOR
Vor Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.32 (-41.82% Downside)
$0.32 (-41.82% Downside)
Blogger Sentiment
Bearish
VOR Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Negative
Last 7 Days ▲ 1.9%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.32%
12-Months-Change
Fundamentals
Return on Equity
-125.43%
Trailing 12-Months
Asset Growth
-34.56%
Trailing 12-Months
Company Description
Vor Biopharma, Inc.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
VOR Stock 12 Month Forecast
Average Price Target
$0.32
▼(-41.82%Downside)
Technical Analysis
Zentalis Pharmaceuticals
―
Pliant Therapeutics
―
C4 Therapeutics
―
Aziyo Biologics
―
Senti Biosciences
―